Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].

[Rinsho ketsueki] The Japanese journal of clinical hematology - 1 Oct 2015

Kubuki Yoko, Hidaka Tomonori, Shimoda Kazuya

Abstract excerpt

Myeloproliferative neoplasms (MPNs) arise from hematopoietic stem cells (HSCs) with genetic abnormalities in combination with mutations in JAK2, MPL or CALR, which induce autosomal JAK-STAT pathway activation, and mutations in epigenetic regulator genes such as TET2 or DNMT3A. The prognosis of patients with polycythemia vera (PV) or essential thrombocythemia (ET) is relatively good, and the therapeutic goal in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epigenesis, Genetic
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hematologic Neoplasms

Share to Janus Kinase 2

Share to Mutation

Share to Myeloproliferative Disorders

Share to Phlebotomy

Share to Prognosis

Source

Identifiers

PMID: 26458438
DOI: 10.11406/rinketsu.56.1996

Genes

CALR
JAK2
MPL
TET2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Myeloproliferative neoplasms: pathophysiology and therapeutic strategy].PMID 26458438Read ↗

[Research status and challenges of advanced myeloproliferative neoplasms].Semantic proximity Read ↗

Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies.Semantic proximity Read ↗

[Research progress on molecular pathogenesis of myeloproliferative neoplasms].Semantic proximity Read ↗

Clinical Features of 294 Turkish Patients with Chronic Myeloproliferative Neoplasms.Semantic proximity Read ↗

[Advances in Pathogenesis of Essential Thrombocythemia - Review].Semantic proximity Read ↗

[Recent findings and advances in treatment of myeloproliferative neoplasms].Semantic proximity Read ↗

Myeloproliferative and lymphoproliferative disorders: State of the art.Semantic proximity Read ↗

[Current Understanding of Myeloproliferative Neoplasm-Related Gene Mutations and Cytokine -Review].Semantic proximity Read ↗

Myeloproliferative Neoplasms: A Contemporary Review.Semantic proximity Read ↗

Myeloproliferative Neoplasms, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.Semantic proximity Read ↗

[BCR::ABL-Negative Triple Negative Myeloproliferative Neoplasm --Review].Semantic proximity Read ↗

Biology and Current Treatment of Myeloproliferative Neoplasms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.